Form 4: Verona Pharma CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Verona Pharma's CEO, David Zaccardelli, sold 2,400 ordinary shares at $5 each, as part of a pre-arranged trading plan.

Summary

• David Zaccardelli, the President and CEO of Verona Pharma, sold 2,400 ordinary shares on November 11, 2024, at a price of $5 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 8, 2024.
• Following the sale, Zaccardelli still beneficially owns 15,202,352 ordinary shares.
• These shares include 3,000,000 underlying Restricted Share Units and 12,202,352 ordinary shares underlying American Depositary Shares (ADSs).

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the pharmaceutical and biotech industries, including companies like Regeneron, Amgen, and Gilead Sciences.
• These plans allow executives to sell shares at predetermined times and prices, avoiding accusations of insider trading based on non-public information.
• The volume of shares sold is relatively small compared to the total holdings of the CEO, which is typical for transactions under these plans.

Stakeholder Impact

• The share sale is unlikely to have a significant impact on shareholders, as it is a small transaction under a pre-arranged plan.

Key Dates

Keywords

Verona Pharma, David Zaccardelli, share sale, Rule 10b5-1, insider trading, ordinary shares, ADS, executive transaction